Abstract:Drug resistance is becoming a major obstacle when treating patients with cancer. Cancer is characterized by an uncontrolled growth of abnormal cells with permanent genome alterations, which lead to severe mutations including resistance mechanisms. Mutations can occur in different resistance pathways, such as inhibition of drug transport, DNA damage repair, drug efflux, EMT (epithelial-mesenchymal transition), drug target alteration and cell death inhibition. Resistance mechanisms are now well studied in vitro, based on mutated cell lines for specific resistance pathways. There is however a gap in our knowledge of resistance mechanisms observed in patient tumor cells. We are challenged to discover cancer resistance treatments in patients and need predictive models of clinical situations. Animal tumor models are the best translational tools to study cancer drug resistance, especially when they closely mimic human pathologies. Such models can bridge the gap between our understanding of cancer resistance in vitro and in tumor patients. In this poster we show different pre-clinical experiments, simulating clinical translational approaches, that led to novel and unique tumor resistant models. Patient Derived Xenograft (PDX) models: Using our breast cancer PDX collection we showed that after repeated treatment with a spindle poison, tumor-bearing mice started to develop resistance and continued tumor growth under drug pressure. Following this successful approach, we initiated the development of a novel ER2-expressing PDX breast tumor model, resistant to hormone therapy by repeated Fulvestrant treatment. Using our colon cancer PDX collection we were able to recapitulate clinical situations by correlating PDX molecular profiles and drug sensitivity. We confirmed the key role of a KRAS mutation in cetuximab resistance. Syngeneic model: In this model, animals were dosed with anti-PDL1 as first line of treatment. All animals were then defined as initial responders or non-responders at the end of the dosing schedule. Following this, a new treatment protocol was initiated with a Tyrosine Kinase inhibitor to study the effect of second line drug treatment in responder and non-responder arms. Human model: In this experiment, we performed a first line Avastin treatment on human colon carcinoma tumor-bearing mice. A tumor resistance to Avastin was observed. During the second line of treatment with a tyrosine kinase inhibitor, we observed an antitumor activity on Avastin resistant animals. In each of these case studies, we developed a novel tumor-resistant mechanism model. In some tumor models, we showed the added value of treating animals with new drugs as second line treatment, after establishing resistance to the first line standard of care treatment. Citation Format: Marc Hillairet de Boisferon, Nicolas Hoffmann, Elodie Rajon, Ismahène Benzaid. Examples of translational preclinical models to mimic cancer drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2826.

Preclinical models in head and neck squamous cell carcinoma

Mouse Models for Head and Neck Squamous Cell Carcinoma

Clinical update on head and neck cancer: molecular biology and ongoing challenges

Engineering models of head and neck and oral cancers on-a-chip

Preclinical human and murine models of hepatocellular carcinoma (HCC)

Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma

Genetically engineered mouse models of head and neck cancers

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges

Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review

Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data

Orthotopic and metastatic tumour models in preclinical cancer research

Reviewing and reconsidering invasion assays in head and neck cancer

Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma

Abstract 2826: Examples of translational preclinical models to mimic cancer drug resistance

The importance of preclinical models in cholangiocarcinoma

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review

Recent advances in preclinical models for lung squamous cell carcinoma